Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01435993
First received: August 25, 2011
Last updated: April 15, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)